Foundations of Pharmacodynamic Systems Analysis
暂无分享,去创建一个
[1] A. Atkinson,et al. Analysis of the contributions of permeability and flow to intercompartmental clearance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[2] W J Jusko,et al. Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. , 1971, Journal of pharmaceutical sciences.
[3] W F Ebling,et al. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies? , 1996, Journal of pharmaceutical sciences.
[4] W. Jusko,et al. Pharmacokinetics of Capacity‐Limited Systems , 1989, Journal of clinical pharmacology.
[5] G. Adair. THE HEMOGLOBIN SYSTEM VI. THE OXYGEN DISSOCIATION CURVE OF HEMOGLOBIN , 1925 .
[6] W J Jusko,et al. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. , 1998, Journal of pharmaceutical sciences.
[7] Wojciech Krzyzanski,et al. Indirect Pharmacodynamic Models for Responses with Multicompartmental Distribution or Polyexponential Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[8] Benjamin Gompertz,et al. XXIV. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. In a letter to Francis Baily, Esq. F. R. S. &c , 1825, Philosophical Transactions of the Royal Society of London.
[9] Grant R. Wilkinson,et al. A physiological approach to hepatic drug clearance , 1975 .
[10] Assessment of Dosing Impact on Intra-Individual Variability in Estimation of Parameters for Basic Indirect Response Models , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[11] DE Mager,et al. Development of Translational Pharmacokinetic–Pharmacodynamic Models , 2008, Clinical pharmacology and therapeutics.
[12] William J. Jusko,et al. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies , 2013, Journal of Pharmacokinetics and Pharmacodynamics.
[13] J. V. van Rossum,et al. Affinity, intrinsic activity and drug interactions. , 1957, Pharmacological reviews.
[14] Torsten Teorell,et al. Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .
[15] Mats O Karlsson,et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. J. Clark. The Rate of Action of Drugs on Cells , 1937 .
[17] E. Starling. On the Absorption of Fluids from the Connective Tissue Spaces , 1896, The Journal of physiology.
[18] Richard R. Almon,et al. Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis I: Mechanistic Disease Progression Model for the Time Course of Collagen-Induced Arthritis in Lewis Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.
[19] R. Ramakrishnan,et al. Basic Pharmacodynamic Models for Agents That Alter Production of Natural Cells , 1999, Journal of Pharmacokinetics and Biopharmaceutics.
[20] J. Black,et al. Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.
[21] A. Fick. V. On liquid diffusion , 1855 .
[22] D. Swinney. The role of binding kinetics in therapeutically useful drug action. , 2009, Current opinion in drug discovery & development.
[23] A. Hill,et al. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .
[24] Donald E Mager,et al. Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. , 2012, Cancer research.
[25] T Iga,et al. Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients. , 1996, Biological & pharmaceutical bulletin.
[26] W. Jusko,et al. Pharmacokinetic/Pharmacodynamic Modeling of GLP-1 in Healthy Rats , 2012, Pharmaceutical Research.
[27] Varun Garg,et al. Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[28] W. Jusko,et al. Inhibition of Rat Splenocyte Proliferation with Methylprednisolone: In Vivo Effect of Liposomal Formulation , 1994, Pharmaceutical Research.
[29] J. Shannon. RENAL TUBULAR EXCRETION , 1939 .
[30] Donald E. Mager,et al. General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[31] T. Brailsford Robertson,et al. The chemical basis of growth and senscence , 1923 .
[32] Jianguo Zhi,et al. Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due toPseudomonas aeruginosa , 1988, Journal of Pharmacokinetics and Biopharmaceutics.
[33] G Levy,et al. Pharmacologic target‐mediated drug disposition , 1994, Clinical pharmacology and therapeutics.
[34] Alan Forrest,et al. Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin , 2004, Antimicrobial Agents and Chemotherapy.
[35] W J Jusko,et al. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.
[36] S. Loewe,et al. Über Kombinationswirkungen , 1926, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.
[37] Richard R Almon,et al. Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis II: Mechanistic Pharmacodynamic Model for Dexamethasone Effects in Lewis Rats with Collagen-Induced Arthritis , 2008, Journal of Pharmacology and Experimental Therapeutics.
[38] G Levy,et al. Kinetics of pharmacologic effects , 1966, Clinical pharmacology and therapeutics.
[39] G. Levy,et al. Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.
[40] W. Jusko,et al. Assessment of Basic Indirect Pharmacodynamic Response Models with Physiological Limits , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[41] Wojciech Krzyzanski,et al. Assessment of Drug Interactions Relevant to Pharmacodynamic Indirect Response Models , 2004, Journal of Pharmacokinetics and Pharmacodynamics.
[42] D. Colquhoun. Pharmacologic Analysis of Drug–Receptor Interaction (3rd edn) , 1998 .
[43] D R Mould,et al. Using Disease Progression Models as a Tool to Detect Drug Effect , 2007, Clinical pharmacology and therapeutics.
[44] W. Jusko,et al. ALGORITHM FOR APPLICATION OF FOURIER ANALYSIS FOR BIORHYTHMIC BASELINES OF PHARMACODYNAMIC INDIRECT RESPONSE MODELS , 2000, Chronobiology international.
[45] William J Jusko,et al. Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[46] W. Jusko,et al. Pharmacoimmunodynamic interactions of interleukin‐10 and prednisone in healthy volunteers , 1999, Clinical pharmacology and therapeutics.
[47] M. Danhof,et al. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. , 1992, The Journal of pharmacology and experimental therapeutics.
[48] Yasuhiko Yamada,et al. Parmacodynamic Analysis of Antiplatelet Effect of Aspirin in the Literature. Modeling Based on Inhibition of Cyclooxygenase in the Platelet and the Vessel Wall Endothelium. , 1996 .
[49] A. Goldstein. The interactions of drugs and plasma proteins. , 1949, The Journal of pharmacology and experimental therapeutics.
[50] W J Jusko,et al. Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.
[51] Renkin Em. Relation of capillary morphology to transport of fluid and large molecules: a review. , 1979 .
[52] Malcolm Rowland,et al. Clearance concepts in pharmacokinetics , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[53] D. DuBois,et al. Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone Effects on iNOS mRNA Expression and Nitric Oxide During LPS-Induced Inflammation in Rats , 2012, Pharmaceutical Research.
[54] Siddharth Sukumaran,et al. Meta-Modeling of Methylprednisolone Effects on Glucose Regulation in Rats , 2013, PloS one.
[55] W. Jusko,et al. Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. , 2004, Journal of veterinary pharmacology and therapeutics.
[56] William J Jusko,et al. Moving from basic toward systems pharmacodynamic models. , 2013, Journal of pharmaceutical sciences.